Press

atai Life Sciences Announces Results from Phase 2a Trial of PCN-101 (R-ketamine) for Treatment-Resistant Depression

Jan 9 • 3 min read

atai Life Sciences (NASDAQ: ATAI), a clinical-stage biopharmaceutical company focused on mental health, announced that, while PCN-101 (R-ketamine) demonstrated signals of efficacy across all timepoints out to two weeks, Perception Neuroscience’s Phase 2a clinical trial did not meet its primary endpoint of a statistically significant change from baseline in participants’ MADRS (Montgomery-Åsberg Depression Rating Scale)…

MAPS PBC Announces Positive Results from Confirmatory Phase 3 “MAPP2” Trial of MDMA-Assisted Therapy for Treatment of PTSD

Jan 9 • 3 min read

MAPS Public Benefit Corporation, a private biopharmaceutical company dedicated to the development and commercialization of psychedelic medicines, announced positive results from MAPP2, a multi-site Phase 3 study of MDMA-assisted therapy for post-traumatic stress disorder (“PTSD”). The study met both the primary endpoint as measured by the change from baseline in Clinician-Administered PTSD Scale for DSM-5…

Filament Health Announces CEO Year-End Letter and Change to Board of Directors

Jan 6 • 2 min read

Filament Health Corp. (OTCQB: FLHLF | NEO: FH | FSE: 7QS), a clinical-stage natural psychedelic drug development company, today announced the distribution of a year-end letter from Chief Executive Officer, Benjamin Lightburn, which can be viewed on Filament’s website. The letter highlights key milestones achieved by the Company including beginning the first ever FDA clinical trial of natural…

Tryp Therapeutics Announces Interim Results for Its Phase II Clinical Trial for the Treatment of Binge Eating Disorder With Psilocybin-Assisted Psychotherapy

Jan 5 • 5 min read

Tryp Therapeutics, Inc. (CSE:TRYP | OTCQB:TRYPF), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, today announced interim results for the first five patients dosed in its Phase II STOP (Study of the Treatment of Overeating utilizing Psilocybin) trial. In collaboration with the University of Florida, the STOP trial…

PsyBio Announces Closing of First Tranche of Private Placement and Provides Corporate Update

Jan 5 • 5 min read

PsyBio Therapeutics Corp. (TSXV: PSYB | OTCQB: PSYBF), an intellectual property driven biotechnology company focused upon discovery and development of novel psycho-targeted therapeutics being designed to improve mental health and neurological conditions, is pleased to announce that the Company has completed the first tranche of its previously announced non-brokered private placement offering of units of…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427